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stable CAD to acute coronary syndromes 
(ACS) and stroke demonstrate that statins 
prevent fatal and non-fatal CVD events and 
reduce all-cause mortality.5,6 Meta-analyses 
of individual trials demonstrate an approx-
imate 23% reduction in CVD events per 
1 mmol/l reduction in LDL-C, with a log 
linear relationship with no threshold below 
which benefit ceases. The benefit is observed 
equally across a range of baseline lipids and 
demographic groups.7
Recent trials have focused on more (vs 
less) intensive statin therapy; for example, 
the median on-treatment LDL-C in the 
intensive arm (atorvastatin 80 mg) of the 
PROVE- IT trial was 1.6 mmol/l vs a LDL-C 
of about 2.4 mmol/l (pravastatin 40 mg) 
resulting in 16% CVD risk reduction.8 
Similarly, in stable CAD (TNT and IDEAL 
trials) a 0.6 mmol/l greater reduction in 
LDL-C (the average on-treatment LDL-C 
was approximately 2 mmol/l) resulted in 
significant reductions in CVD events with 
intensive therapy (atorvastatin 80 mg). In 
contrast, the AZ (ACS patients) and the 
SEARCH (stable CAD patients) trials failed 
to demonstrate a benefit of simvastatin 
80 mg vs 20 mg, largely because of the very 
small incremental reduction in LDL-C.7,9 
Importantly, the risk of myopathy with sim-
vastatin 80 mg was 2,000-fold higher than 
with atorvastatin 80 mg, resulting in the US 
Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) warning 
against the use of simvastatin 80 mg. The 
Medicines and Healthcare Products 
Regulatory Agency (MHRA) guidance warns 
against co-prescription of a number of car-
diovascular drugs, including calcium antag-
onists and amiodarone, with simvastatin at 
doses above 20 mg. To date, trials have not 
been designed to assess the benefit of any 
specific LDL-C target, hence guidance on 
specific targets is based on extrapolations 
from trial data and the absolute risk of the 
patient, with lower LDL-C goals advised for 
those at highest risk – for example, estab-
lished CVD. NICE recommends an LDL-C 
goal of 2 mmol/l for such high-risk patients, 
whereas the ESC/EAS recommend a lower 
target of 1.8 mmol/l (and 2.5 mmol/l for 
high-risk primary prevention patients).
There is no evidence for excess risk of liver 
or muscle side effects or for excess risk of 
cancers with low achieved LDL-C; side effects 
fasting non-HDL-C (TC-HDL-C) is the 
preferred measure of atherogenic risk.3 Both 
non-HDL-C and apo B can be obtained 
from non-fasting samples, but the latter is 
more expensive, less available and not stand-
ardised. The European Society of Cardiology 
(ESC)/European Atherosclerosis Society 
(EAS) guidelines recommend non-HDL-C 
as a secondary target when HDL-C is low or 
TG is high, or both. Several statin trials now 
suggest that non-HDL-C is a better marker 
of on-treatment risk than LDL-C.4 Finally, 
among subjects with a family history of pre-
mature CVD or elevation in lipoprotein a 
(Lp(a)), the ESC/EAS recommend meas-
uring Lp(a) levels, with levels of >50 mg/dl 
identifying high-risk groups. 
Lifestyle adjustment
Cardiovascular disease prevention begins 
with lifestyle change: smoking cessation, 
alcohol consumption, blood pressure, diet 
and exercise (which affect body mass index 
and blood glucose), should be addressed. 
The National Institute for Health and Care 
Excellence (NICE) guidelines recommend 
a diet with total fat intake of <30% and 
saturated fats <10% of total energy intake, 
dietary cholesterol of <300 mg/day and 
replacement of saturated fat with mono- 
and poly-unsaturated fats. Such measures 
reduce cholesterol modestly, but response 
varies considerably between individuals.
Risk assessment
Lipid modification therapy is indicated as 
part of primary prevention for adults with 
a predicted 20% or greater 10-year risk of 
developing CVD. Several risk equations 
exist: Framingham, QRISK (UK specific) 
and SCORE (European). LMT must be 
initiated simultaneously with lifestyle 
advice for those with established CVD. 
Chronic kidney disease (CKD) and Lp(a) 
levels do not contribute to many risk 
engines, but can potentially reclassify an 
intermediate- into a high-risk individual.
Statin therapy
Statins are the cornerstone of LMT and 
more than 20 trials conducted in settings 
ranging from primary prevention and 
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Introduction
Cardiovascular disease (CVD), particularly 
coronary artery disease (CAD), is the 
leading cause of death and disability in the 
western world and contributes substan-
tially to healthcare budgets.1 Lipid modifi-
cation therapies (LMTs) have revolution-
ised contemporary approaches to primary 
and secondary prevention of CVD.
What should we measure?
Total cholesterol has a log linear relationship 
with CAD with no apparent threshold below 
which risk diminishes. However, total cho-
lesterol incorporates both the atherogenic 
components–low-density lipoprotein (LDL), 
intermediate-density lipoprotein (IDL) and 
very-low-density lipoprotein (VLDL) cho-
lesterol (collectively known as non-high-
density lipoprotein cholesterol [non-HDL-
C] – and the protective factor high-density 
lipoprotein (HDL) and its measure HDL-C. 
Therefore, measurements of either apolipo-
proteins (apo) (one apo B per LDL, IDL and 
VLDL particle, or apo A as a measure of the 
number of HDL particles) or cholesterol 
content (non-HDL-C and HDL-C) are more 
informative. Collective evidence demon-
strates that CAD risk per 1 standard devia-
tion (SD) is identical for apo B and non-
HDL-C and 30% stronger than for LDL-C; 
apo A and HDL-C offer similar magnitudes 
of protection.2 As measurement of LDL-C 
requires a fasting sample, is calculated 
(TC-HDL-C – (TG/5), where TC-HDL-C is 
total cholesterol HDL-C and TG is triglyc-
eride) rather than directly measured and 
incompletely captures atherogenic risk, non-
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for statin-intolerant subjects, but the evi-
dence base is unclear. Niacin, which lowers 
LDL-C by 20%, raises HDL-C by 30% and 
lowers Lp(a) by 25%, has recently been 
withdrawn in several European countries 
because of a lack of contemporary out-
comes data. Therapeutic options being 
licenced for rare conditions such as 
homozygous familial hypercholesterol-
aemia include mipomersen which is an 
antisense inhibitor of apo B, which reduces 
transcription of the protein scaffold, pro-
viding 30% lowering of LDL-C and the 
microsomal triglyceride transfer protein 
(MTP) inhibitor lomitapide, which 
reduces LDL-C by about 50% but does 
lead to an increase in hepatic fat. More 
exciting are the monoclonal PCSK9 anti-
bodies given by subcutaneous injection 
every 2–4 weeks that increase LDL receptor 
survival time and reduce LDL-C by a fur-
ther 70% in patients on optimal statin 
therapy. 
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may be dose-related but, in general, statins 
are safe and well tolerated even at high doses 
(except simvastatin) and side effects are usu-
ally fully reversible with cessation of 
therapy.10,11 Myopathy and rhabdomyolysis 
are rare at standard doses (about 0.1% per 
year)5 but the rates of myalgia are higher 
(about 4%).12 Conditions that increase the 
likelihood of statin-induced myalgia or 
myopathy, such as alcohol excess, hypothy-
roidism, vitamin D deficiency and acute viral 
illness, should be ruled out. Medications may 
affect statin metabolism (eg gemfibrozil, 
cyclosporine, amiodarone, macrolides, anti-
biotics, verapamil, warfarin and protease 
inhibitors), and a high intake of grapefruit 
juice may have an impact on CYP3A4 in the 
liver. Asymptomatic increases in hepatic 
transaminases are dose dependent and revers-
ible with down-titration or discontinuation. 
Hepatitis attributable to drugs is rare 
(0.001%).13 As the evidence base for statins 
far exceeds any other LMT, intolerant patients 
should try at least one other statin at a lower 
dose. If this fails, suggest a weekly or twice 
weekly dose of a statin with a longer half-life, 
such as rosuvastatin 5 mg or atorvastatin 10 
mg, before trying monotherapy with 
ezetimibe or bile acid sequestrants such as 
colesevalam. 
In the JUPITER trial, it was observed that 
rosuvastatin increased the risk of developing 
diabetes mellitus (DM) compared with pla-
cebo.14 In two large-scale meta-analyses of 
all randomised controlled trials, this obser-
vation was established as a class and dose 
effect, where statins increased the relative 
risk of DM by 9% at a standard dose and by 
12% when comparing high with standard 
doses. In absolute terms, the risk is low and 
offset by the greater number of CVD events 
prevented, approximately five per case of 
DM (for statin vs placebo) or three CVD 
events per case of DM (for high vs standard 
dose). Therefore, in patients with high or 
existing cardiovascular risk, current clinical 
practice should not change, but initiation of 
therapy in low-risk subjects should be con-
sidered on a case by case basis, with annual 
blood glucose monitoring.15 
Maximising cardiac risk reduction
Optimising evidence-based treatments 
remains a challenge; for example, data from 
EuroASPIRE III showed that although 80% 
of patients with CVD were treated with 
LMT, only 34% achieved lipid targets.16 
This represents a significant burden of 
residual but modifiable risk correctable by 
optimising the statin dose. Absolute risk 
depends on both the number of uncon-
trolled modifiable risk factors and the pres-
ence of non-modifiable risk factors such as 
DM and stage 3 CKD, hence any approach 
to CVD risk reduction should aim to opti-
mise lifestyle and control all risk factors. 
Treatments need to be tailored to indi-
vidual patients and clinicians should target 
high-risk subjects (with multiple risk fac-
tors) for more intensive therapies, lower 
lipid targets and, importantly, should rec-
ognise that LDL-C is a suboptimal target 
for assessing efficacy of LMT when HDL is 
low (for example, in patients with obesity, 
DM, CKD and those with high triglycer-
ides) and instead use non-HDL-C. 
Alternative lipid-modification 
strategies
The evidence base for other LMTs is small 
and they are generally less effective. 
Nevertheless, there is consistent data that 
in addition to statins, fibrates reduce CVD 
risk by about one-third when TG is >1.7 
mmol/l and HDL-C is <1 mmol/l. Non-
fatal events and revascularisation may be 
reduced but generally not CVD death. 
Ezetimibe and colesevelam each lower 
LDL-C by around 20% and are often used 
in addition to statins or as monotherapy 
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